Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to buy. On October 21, Exelixis, Inc. (NASDAQ:EXEL) got upgraded to Outperform from Market Perform by Leerink Partners.








